Retatrutide
Triple agonist (GLP-1 / GIP / Glucagon)
4.9 — read reviewsNext-generation fat loss research.
An investigational triple receptor agonist that activates GLP-1, GIP, and glucagon pathways simultaneously. Trial data shows the largest weight-loss results recorded for a peptide therapeutic to date.
Researched Benefits
- Substantial fat loss
- Appetite suppression
- Improved glucose control
- Metabolic rate support
Research dosing: titrated weekly subcutaneous injection, typically 2–12 mg.
~6 days (weekly dosing)
For laboratory research use only. Not for human consumption, diagnosis, or treatment.
Dosing Reference
- Typical Dose
- Titrated 2 mg → 12 mg
- Frequency
- Weekly subcutaneous injection
- Route
- Subcutaneous (abdomen, thigh)
- Cycle Length
- Titrate up by 2 mg every 4 weeks
Side Effects & Cautions
- •Nausea (especially during titration)
- •Loss of appetite
- •Constipation or diarrhea
- •Injection-site reaction
- •Fatigue at higher doses
- •History of medullary thyroid carcinoma research
- •Active pancreatitis
- •Severe gastrointestinal disease
- •Pregnancy/lactation: not studied
Reconstitution Calculator
Convert vial size + BAC water into draw units.
For laboratory reference only. Verify all calculations independently. Atlas Labs products are sold for research use, not human consumption.
Lab-verified quality
Every lot ships with a downloadable Certificate of Analysis.
- HPLC purity & identity by Janoshik Analytical
- Mass-spectrometry confirmation of sequence
- LAL endotoxin testing per lot
- Cold-chain shipping with thermal protection
Research Citations
Peer-reviewed studies referenced in our product summary.
Frequently Stacked With
Researchers often combine Retatrutide with these peptides.
Frequently Asked Questions
Customer Reviews
- No reviews yet — be the first to share your experience.